First Tracks Biotherapeutics (NASDAQ: TRAX) has recently received a number of price target changes and ratings updates:
- 10/17/2026 – First Tracks Biotherapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
- 10/16/2026 – First Tracks Biotherapeutics had its price target raised by Leerink Partners from $70.00 to $90.00. They now have an “outperform” rating on the stock.
- 10/13/2026 – First Tracks Biotherapeutics had its “outperform” rating reaffirmed by Evercore. They now have a $70.00 price target on the stock.
- 10/13/2026 – First Tracks Biotherapeutics had its price target raised by Canaccord Genuity Group from $50.00 to $60.00. They now have a “buy” rating on the stock.
- 10/12/2026 – First Tracks Biotherapeutics had its price target raised by Wells Fargo & Company from $62.00 to $70.00. They now have an “overweight” rating on the stock.
- 10/9/2026 – First Tracks Biotherapeutics had its price target raised by Wells Fargo & Company to $62.00. They now have an “overweight” rating on the stock.
- 10/8/2026 – First Tracks Biotherapeutics was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
- 9/30/2026 – First Tracks Biotherapeutics is now covered by Canaccord Genuity Group. They set a “buy” rating and a $50.00 price target on the stock.
- 9/18/2026 – First Tracks Biotherapeutics is now covered by Evercore. They set an “outperform” rating and a $65.00 price target on the stock.
- 9/18/2026 – First Tracks Biotherapeutics is now covered by Evercore. They set an “outperform” rating and a $65.00 price target on the stock.
- 9/16/2026 – First Tracks Biotherapeutics is now covered by Guggenheim. They set a “buy” rating and a $100.00 price target on the stock.
- 9/16/2026 – First Tracks Biotherapeutics is now covered by UBS Group. They set a “buy” rating on the stock.
- 9/16/2026 – First Tracks Biotherapeutics is now covered by Guggenheim. They set a “buy” rating and a $100.00 price target on the stock.
- 9/16/2026 – First Tracks Biotherapeutics is now covered by Guggenheim. They set a “buy” rating and a $100.00 price target on the stock.
- 9/5/2026 – First Tracks Biotherapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
First Tracks Biotherapeutics Trading Down 0.1%
Shares of NASDAQ:TRAX opened at $45.05 on Tuesday. The firm has a market capitalization of $1.89 billion and a price-to-earnings ratio of -24.48. The business’s fifty day simple moving average is $38.96. First Tracks Biotherapeutics has a 52 week low of $14.72 and a 52 week high of $49.91.
First Tracks Biotherapeutics (NASDAQ:TRAX – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.21). Research analysts anticipate that First Tracks Biotherapeutics will post -4.31 earnings per share for the current fiscal year.
Insider Buying and Selling
First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.
Read More
- Five stocks we like better than First Tracks Biotherapeutics
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AIāThese 5 Stocks Are Getting Paid
Receive News & Ratings for First Tracks Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Tracks Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
